Login to Your Account

Clinic Roundup

Thursday, August 2, 2012
• InSite Vision Inc., of Alameda, Calif., said it started enrollment in the first Phase III trial of BromSite (ISV-303) for the reduction of pain and inflammation after cataract surgery.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription